Life Biosciences secures $80M to test aging-reversal gene therapy
TL;DR Summary
David Sinclair’s Life Biosciences raised $80 million to move a one-time anti-aging gene therapy into clinical testing, pursuing partial epigenetic reprogramming with Yamanaka factors (Oct4, Sox2, Klf4) delivered by AAV to rewind cellular aging.
- David Sinclair startup raises $80M for clinical test of anti-aging gene therapy Endpoints News
- Can aging be reversed? First human trials set to begin The News International
- Life Biosciences secures $80 million Series D financing The Pharma Letter
- Life Biosciences lands $80m to push cell reset therapy Longevity.Technology
- Life Biosciences Raises $80M in Series D Funding FinSMEs
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
2 min
vs 3 min read
Condensed
93%
519 → 34 words
Want the full story? Read the original article
Read on Endpoints News